scholarly journals Research work of Prof. Yoshioka on high-dose-rate brachytherapy monotherapy for prostate cancer

Impact ◽  
2021 ◽  
Vol 2021 (5) ◽  
pp. 25-27
Author(s):  
Yasuo Yoshioka
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
Treatment Options ◽  
Research Work ◽  
High Dose Rate ◽  
High Dose ◽  
Effective Treatment Option ◽  
Ldr Brachytherapy ◽  
Radiation Sources

Prostate cancer is one of the most common types of cancer. If identified early, treatment can be very effective, but morbidity rates are higher in older patients and in cases where the cancer is identified in the later stages. Three main treatment options are surgery, external beam radiotherapy and brachytherapy. Professor Yasuo Yoshioka, Radiation Oncology Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, believes brachytherapy to be the most effective treatment option for prostate cancer patients and is working to improve the methods by which brachytherapy is performed in order to further enhance its effectiveness, while reducing the amount of damage to the patient during the course of treatment. Yoshioka and his team are focused on high-dose-rate (HDR) brachytherapy as they believe it has advantages over low-dose-rate (LDR) brachytherapy, including its ability to treat advanced-stage patients, the ability to adjust the strength of radiation at each source position and the fact that no radiation sources will be left in the patient's body after treatment. Yoshioka reported the world's first HDR monotherapy experience for prostate cancer and, over the past decade, he and his team have been refining the procedure in order to maximise the effect of the treatment while minimising damage to the patient.

scholarly journals A critical evaluation of the clinical value of high-dose rate brachytherapy in the treatment of prostate cancer

2006 ◽  
Vol 5 (4) ◽  
pp. 227-232 ◽  
Author(s):  
E. C. Sharman
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Large Fraction ◽  
External Beam Radiotherapy ◽  
Locally Advanced ◽  
Critical Evaluation ◽  
High Dose Rate ◽  
High Dose ◽  
Hdr Brachytherapy ◽  
Ldr Brachytherapy

Prostate cancer has been treated with low-dose rate (LDR) brachytherapy for early localised disease in the form of permanent seed implants, with all its inherent problems in terms of dosimetry and seed migration. High-dose rate (HDR) brachytherapy has mainly been utilised as a boost to external beam radiotherapy (EBRT) in patients with locally advanced disease. However, limited studies investigating HDR as a monotherapy for early local disease are yielding promising results in terms of biochemical control and reduced toxicity. With the ability to optimise the plan and conform the dose, dose escalation can be achieved whilst sparing normal tissue. Recent studies to assess the α/β ratio of prostate cancer have shown this to be low, making this tumour sensitive to large fractions or hypofractionation. The HDR delivery and large fraction sizes may be advantageous in tumours sensitive to radiation fraction size making HDR brachytherapy the treatment of choice over LDR brachytherapy and EBRT.

scholarly journals Brachytherapy for Prostate Cancer: A Systematic Review

2009 ◽  
Vol 2009 ◽  
pp. 1-11 ◽  
Author(s):  
Georgios Koukourakis ◽  
Nikolaos Kelekis ◽  
Vassilios Armonis ◽  
Vassilios Kouloulias
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Low Dose ◽  
External Beam Radiotherapy ◽  
Treatment Options ◽  
High Dose Rate ◽  
High Dose ◽  
Invasive Treatment ◽  
Low Dose Rate ◽  
Long Term Treatment

Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. To a great extend due to patient lead advocacy for minimally invasive treatment options, high-quality prostate implants have become widely available in the US, Europe, and Japan. High-dose-rate (HDR) afterloading brachytherapy in the management of localised prostate cancer has practical, physical, and biological advantages over low-dose-rate seed brachytherapy. There are no free live sources used, no risk of source loss, and since the implant is a temporary procedure following discharge no issues with regard to radioprotection use of existing facilities exist. Patients with localized prostate cancer may benefit from high-dose-rate brachytherapy, which may be used alone in certain circumstances or in combination with external-beam radiotherapy in other settings. The purpose of this paper is to present the essentials of brachytherapies techniques along with the most important studies that support their effectiveness in the treatment of prostate cancer.

scholarly journals Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Jörg Tamihardja ◽  
Paul Lutyj ◽  
Johannes Kraft ◽  
Dominik Lisowski ◽  
Stefan Weick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
Localized Prostate Cancer ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Brachytherapy Boost ◽  
Gi Toxicity

PurposeEvaluation of clinical outcome of two-weekly high-dose-rate brachytherapy boost after external beam radiotherapy (EBRT) for localized prostate cancer.Methods338 patients with localized prostate cancer receiving definitive EBRT followed by a two-weekly high-dose-rate brachytherapy boost (HDR-BT boost) in the period of 2002 to 2019 were analyzed. EBRT, delivered in 46 Gy (DMean) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D90%) two and four weeks after EBRT. Androgen deprivation therapy (ADT) was added in 176 (52.1%) patients. Genitourinary (GU)/gastrointestinal (GI) toxicity was evaluated utilizing the Common Toxicity Criteria for Adverse Events (version 5.0) and biochemical failure was defined according to the Phoenix definition.ResultsMedian follow-up was 101.8 months. 15 (4.4%)/115 (34.0%)/208 (61.5%) patients had low-/intermediate-/high-risk cancer according to the D`Amico risk classification. Estimated 5-year and 10-year biochemical relapse-free survival (bRFS) was 84.7% and 75.9% for all patients. The estimated 5-year bRFS was 93.3%, 93.4% and 79.5% for low-, intermediate- and high-risk disease, respectively. The estimated 10-year freedom from distant metastasis (FFM) and overall survival (OS) rates were 86.5% and 70.0%. Cumulative 5-year late GU toxicity and late GI toxicity grade ≥ 2 was observed in 19.3% and 5.0% of the patients, respectively. Cumulative 5-year late grade 3 GU/GI toxicity occurred in 3.6%/0.3%.ConclusionsTwo-weekly HDR-BT boost after EBRT for localized prostate cancer showed an excellent toxicity profile with low GU/GI toxicity rates and effective long-term biochemical control.

Sign in / Sign up

Export Citation Format

Share Document